MedTrace Logo

Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura

NCT00877838 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-07-28

No results posted yet for this study

Summary

The following study is being conducted to explore the safety and effectiveness of a new chemical entity called NXN-188 in subjects with a history of migraine with aura. In this study subjects will treat two attacks of migraine with aura during the aura phase - once with placebo and once with NXN-188.

Conditions

  • Migraine With Aura

Interventions

DRUG

NXN-188

NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.

DRUG

Placebo

Gelatin capsules resembling the ones containing the active substance

Sponsors & Collaborators

  • NeurAxon Inc.

    collaborator INDUSTRY

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Peer Tfelt-Hansen, MD, Dr Med Sci · Department of Neurology, Glostrup Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-03-31
Completion
2010-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00877838 on ClinicalTrials.gov